Sepracor Inc.
Sepracor Announces New Drug Submission NDS to Health Canada for STEDESA(TM) as Adjunctive Treatment for Epilepsy
Published in Medical Letter on the CDC and FDA, August 30th, 2009
Sepracor Inc. (Nasdaq: SEPR) announced that its Canadian subsidiary, Sepracor Pharmaceuticals, Inc. (SPI; formerly Oryx Pharmaceuticals, Inc.), has submitted an application to the Therapeutic Products Directorate (TPD) of Health Canada for eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. The proposed trade name for eslicarbazepine acetate in both the U.S. and Canada is STEDESA™.
"The STEDESA submission represents SPI's continuing commitment to providing Canadians with important new therapies in the treatment of central nervous system disorders, which is a therapeutic area in which we already have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- CombinatoRx, Incorporated
CombinatoRx Reports Financial Results for the Second Quarter 2009 - ETHICON, Inc.
ETHICON Introduces New Product Enhancement and Packaging for BIOPATCH(R) to Improve Ease of Application for Patients with Catheters - Hyponatremia
New hyponatremia study results reported from Emory University - Life Sciences
Ethicon Introduces New Product Enhancement and Packaging for Biopatch(R) to Improve Easeof Application for Patients with Catheters - Life Sciences
Studies from V.L. Fulgoni and colleagues provide new data on life sciences - OmniComm Systems, Inc.
Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
